VirtualCancerCure
Home of CancerMate: computational prognosis of neoadjuvant therapies for breast cancer
![Breast cancer is a single-phase biomaterial featuring a \emph{cancer cells population}, that grows and invades the Region of Interest (ROI). Moreover, during therapy $n$ \emph{drug species} are administered: in the BC context, $n$ can be generally up to 3. When $\phi_\mathrm{c}$ represent the cancer cell density, or dimensionless volume in the biological matrix, Gompertzian logistics can be employed to describe the evolution (change rate) of cell density:\begin{equation*}\frac{\mathrm{d}\phi_\mathrm{c}}{\mathrm{d}t}=-r_\mathrm{c}\phi_\mathrm{c}\ln\left(\frac{\phi_\mathrm{c}}{K}\right)\end{equation*}where $1/r_\mathrm{c}$ is a timescale constant and $K$ is the carrying capacity of the biological matrix, or the available ROI where the governing Equations are applied.\\The governing PDE for reaction-diffusion of tumoral biomass transport, in space $\mathbf{x}$ and time $t$, can be applied to the ROI in terms of dimensionless cell density:\begin{equation*}\frac{\partial\phi_\mathrm{c}}{\partial t}=\nabla\cdot\left[D_\mathrm{c}\left(\mathbf{x},t\right)\nabla\phi_\mathrm{c}\right]+R_\mathrm{c}\end{equation*}as well as $n$ governing PDEs of drug transport, in terms of drug concentration, with $j$ a drug counter:\begin{equation*}\frac{\partial\phi_{\mathrm{d}j}}{\partial t}=\nabla\cdot\left[D_{\mathrm{d}j}\left(\mathbf{x},t\right)\nabla\phi_{\mathrm{d}j}\right]+R_{\mathrm{d}j}\end{equation*}$D$s are the effective diffusion coefficients for each species\slash drug, while source terms $R$s can be specified as follows, to account for creation\slash destruction of $\phi_\mathrm{c}$ and $\phi_{\mathrm{d}j}$, respectively:\begin{equation*}R_\mathrm{c}=-r_\mathrm{c}\phi_\mathrm{c}\ln\left(\frac{\phi_\mathrm{c}}{K}\right)-\sum_j^n\left(\epsilon_{\mathrm{PD}j}\phi_{\mathrm{d}j}\right);\quad R_{\mathrm{d}j}=f_j\left(t\right)-\epsilon_{\mathrm{PK}j}\phi_{\mathrm{d}j}\end{equation*}Here, $r_\mathrm{c}$ is a biological tumor conversion rate: a function of a nominal value $r_\mathrm{c0}$ that reflects the macroscopic classification of breast cancer for each patient (given by the combination of histopathological type, grade and stage of the tumor, and expression of related proteins and genes) and the basal values of the personalized Ki67 and TILs clinical biomarkers; while $\epsilon_{\mathrm{PD}j}$ is a mass-mediated drug efficiency, or aggregated pharmacodynamics behaviour (PD) of the $j$-th drug; relevant to the stratification of patients for the best therapy identification, this parameter reflects the personalized biological response to the therapy, providing the reduction of tumor volume in time; then $f_j\left(t\right)$ is the regimen indicator or therapy modulation function, for each $j$-th drug, and finally $\epsilon_{\mathrm{PK}j}$ is the known effect of the clearance, or pharmacokinetics behaviour (PK) for each $j$-th drug, generally depending on each patient's weight and body surface area and the available drug specs.](https://www.virtualcancercure.com/wp-content/ql-cache/quicklatex.com-4aab88b331a1ca1288510ad13ac66bba_l3.png "Rendered by QuickLaTeX.com")
